Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Receivables (2024 - 2025)

Kiora Pharmaceuticals' Receivables history spans 2 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Receivables rose 153.29% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $1.5 million, up 153.29%, while the annual FY2025 figure was $1.5 million, 153.29% up from the prior year.
  • Receivables reached $1.5 million in Q4 2025 per KPRX's latest filing, up from $1.2 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $2.4 million in Q2 2025 to a low of $189905.0 in Q1 2024.